EUVIMEDEUVIMED entdecken
Multizentrische StudieBeobachtungsstudieOpen Access · CC BY-NC-ND 4.0

Prognostic significance of peripheral blood biomarkers in patients with advanced renal cell carcinoma treated with nivolumab and ipilimumab—a polish multicenter, observational study

Renata Pacholczak-Madej, Artur Drobniak, Aleksandra Grela-Wojewoda, Jacek Calik, Natalia Versuti Viegas, Daria Tusień-Małecka, Jolanta Dobrzańska, Agnieszka Roman, Anna Bidas, Marek Szwiec, Angelika Gawlik-Urban, Jerzy Walocha und 3 weitere

Clinical and Experimental Medicine · 23.01.2025 · 25 (1)

DOI: 10.1007/s10238-024-01544-4 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Clinical and Experimental Medicine, online erschienen am 23.01.2025. Verfasst von Renata Pacholczak-Madej und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Chemotherapy, The District Hospital, Sucha Beskidzka, Poland. Renata.pacholczak@uj.edu.pl. Hauptthemen laut MEDLINE: Carcinoma, Renal Cell, Nivolumab, Ipilimumab, Kidney Neoplasms. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 43 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Immune checkpoint inhibitors have improved the treatment of metastatic renal cell carcinoma (RCC), with the combination of nivolumab (NIVO) and ipilimumab (IPI) showing promising results. However, not all patients benefit from these therapies, emphasizing the need for reliable, easily assessable biomarkers. This multicenter study involved 116 advanced RCC patients treated with NIVO + IPI across nine oncology centers in Poland. Blood markers such as neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), and lymphocyte-to-monocyte ratio (LMR), eosinophils, and monocytes were assessed at baseline, after three months, and before disease progression (PD). The prognostic significance of these parameters was analyzed using linear regression, Kaplan-Meier survival analysis, and Cox regression models. After a median follow-up of 11.8 months, the progression-free survival (PFS) was 12.8 months (95% confidence interval [CI] 5.7-28.1), while the overall survival (OS) was 27.3 months (95% CI 16-not reached). Patients with an NLR increase of ≥ 25% had a PFS of 8.2 (3.1-24.7) months compared to 17.5 (8.6-28.1) months in those with a rise in < 25% (p = 0.015). Similarly, a ≥ 25% increase in PLR was linked to a PFS of 6.8 (2.8-8.3) months compared to 17.4 (8.4-28.1) months (p < 0.001). Multivariate analysis confirmed PLR as an independent predictor of PFS (HR 2.9, 95% CI 1.5-5.6, p = 0.001), while elevated eosinophil levels were associated with a reduced risk of death (HR 0.2, 95% CI 0.04-0.9, p = 0.05). No other analysis was statistically significant. NLR, PLR, and eosinophil levels may serve as valuable biomarkers for predicting treatment response in RCC patients receiving NIVO + IPI.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Renal CellNivolumabIpilimumabKidney NeoplasmsBiomarkers, TumorAntineoplastic Combined Chemotherapy ProtocolsHumansMaleFemaleMiddle AgedAgedPrognosisPolandAdultAged, 80 and overNeutrophils

Stichwörter der Autor:innen

EosinophilsImmune checkpoint inhibitorsLymphocyte-to-monocyte ratioNeutrophil-to-lymphocyte ratioPlatelet-to-lymphocyte ratioPrognostic factorsRenal cell carcinoma

Substanzen

NivolumabIpilimumabBiomarkers, Tumor

Autor:innen und Institutionen

  • Department of Chemotherapy, The District Hospital, Sucha Beskidzka, Poland. Renata.pacholczak@uj.edu.pl.
  • Department of Gynecological Oncology, Maria Sklodowska-Curie National Research Institute of Oncology, Krakow Branch, Poland. Renata.pacholczak@uj.edu.pl.
  • Department of Anatomy, Medical College, Jagiellonian University, 31-115, Krakow, Poland. Renata.pacholczak@uj.edu.pl.
  • Department of Chemotherapy, The District Hospital, Sucha Beskidzka, Poland.
  • Department of Clinical Oncology, Maria Sklodowska-Curie National Research Institute of Oncology, Krakow Branch, Poland.
  • Department of Clinical Oncology, University Hospital in Wroclaw, Wrocław, Poland.

Zitieren

APA

Pacholczak-Madej, R., Drobniak, A., Grela-Wojewoda, A., Calik, J., Viegas, N. V., Tusień-Małecka, D., Dobrzańska, J., Roman, A., Bidas, A., Szwiec, M., Gawlik-Urban, A., Walocha, J., Blecharz, P., Stokłosa, Ł., & Puskulluoglu, M. (2025). Prognostic significance of peripheral blood biomarkers in patients with advanced renal cell carcinoma treated with nivolumab and ipilimumab—a polish multicenter, observational study. Clinical and Experimental Medicine, 25(1). https://doi.org/10.1007/s10238-024-01544-4

Vancouver

Pacholczak-Madej R, Drobniak A, Grela-Wojewoda A, Calik J, Viegas NV, Tusień-Małecka D, et al. Prognostic significance of peripheral blood biomarkers in patients with advanced renal cell carcinoma treated with nivolumab and ipilimumab—a polish multicenter, observational study. Clinical and Experimental Medicine. 2025;25(1). doi:10.1007/s10238-024-01544-4

BibTeX
@article{PacholczakMadej2025,
  author = {Pacholczak-Madej, Renata and Drobniak, Artur and Grela-Wojewoda, Aleksandra and Calik, Jacek and Viegas, Natalia Versuti and Tusień-Małecka, Daria and Dobrzańska, Jolanta and Roman, Agnieszka and Bidas, Anna and Szwiec, Marek and Gawlik-Urban, Angelika and Walocha, Jerzy and Blecharz, Paweł and Stokłosa, Łukasz and Puskulluoglu, Mirosława},
  title = {Prognostic significance of peripheral blood biomarkers in patients with advanced renal cell carcinoma treated with nivolumab and ipilimumab—a polish multicenter, observational study},
  journal = {Clinical and Experimental Medicine},
  year = {2025},
  volume = {25},
  number = {1},
  doi = {10.1007/s10238-024-01544-4}
}
Kostenlos starten →